Hero Background

2026 Annual Report

Transforming diagnostics around the world from the south-west corner of Surrey

Bioventix continues to evolve from the generation of value from our historical product portfolio of core antibodies into a business with increasing expertise and reach in the creation of antibodies for application in the diagnosis of a range of neurological conditions and diseases.

2026 in numbers

A snapshot of some key figures from the year ending June 2026.

12

The composition of the Bioventix team remains at 12 full-time equivalents.

£257k

Tau / neuro royalties increased threefold from 2024/25

5 Tau antibodies

Being made at scale

£7.8M

Paid to shareholders in dividends

Financial year 2025/26

A significant 
scientific development

A significant scientific development during the year has been the emergence of “eMTBR-Tau” immunoassays from Alamar Biosciences and Spear Bio. Whilst p-Tau217 tracks AD through early amyloid pathology and later Tau tangle pathology, eMTBR-Tau is more specific for later stage disease caused by Tau tangles. eMTBR-Tau assays could therefore be useful to confirm clinical assessment of cognition in later stage disease. In addition, eMTBR-Tau could be helpful in ruling out candidates forclinical trials and future therapeutic options.

We believe we have made excellent eMTBR SMAs and are delighted to have played our part in the eMTBR-Tau discovery process.

The overall response from customers to our various Tau evaluation samples of SMAs supplied for RuO assays has been positive and we are encouraged by our growing footprint in these areas.

Our purpose at Bioventix is to create, manufacture and supply high affinity sheep monoclonal antibodies for use in diagnostic applications. The use of our products in In Vitro Diagnostic (“IVD”) tests allows clinicians to accurately and economically diagnose and then appropriately treat life changing diseases and conditions thereby improving outcomes and the lives of populations across the world.

Highlights from 2026 and looking ahead

Bioventix continues to evolve from the generation of value from our historical product portfolio of core antibodies into a business with increasing expertise and reach in the creation of antibodies for application in the diagnosis of a range of neurological conditions and diseases.

Positive customer response to various Tau evaluation samples.

We are encouraged by our growing footprint in these areas.

Pyrene lateral flow system for industrial pollution biomonitoring is proceeding steadily.

We plan to continue field trials with
firefighters during 2027.

Projects running in the field of vascular dementia, rarer dementias and peripheral neuropathies.

In addition to Alzheimer’s disease.

University of Gothenburg collaboration key to growing success.

We have been working with the University of Gothenburg since early 2020 to create new antibodies to Tau and to develop prototype assays for use in Alzheimer’s disease.

Lateral flow assay for paracetamol which is intended to calibrate to 0.1-1.0% of raw sewage contamination in “fresh” waters.

We plan to work with volunteer groups to conduct field trials aimed at better understanding the link between
paracetamol levels and Escherichia coli (“E.coli”).

Positive customer response to various Tau evaluation samples.

We are encouraged by our growing footprint in these areas.

Pyrene lateral flow system for industrial pollution biomonitoring is proceeding steadily.

We plan to continue field trials with
firefighters during 2027.

Projects running in the field of vascular dementia, rarer dementias and peripheral neuropathies.

In addition to Alzheimer’s disease.

University of Gothenburg collaboration key to growing success.

We have been working with the University of Gothenburg since early 2020 to create new antibodies to Tau and to develop prototype assays for use in Alzheimer’s disease.

Lateral flow assay for paracetamol which is intended to calibrate to 0.1-1.0% of raw sewage contamination in “fresh” waters.

We plan to work with volunteer groups to conduct field trials aimed at better understanding the link between
paracetamol levels and Escherichia coli (“E.coli”).

Looking Ahead

We plan to develop our neurological pipeline further through our on-going collaboration with the University of Gothenburg.

In addition, as the frontier of neuroscience and the blood-based biomarker field evolves, we will seek additional opportunities that may emerge from other collaborators in this rapidly developing area.

Peter Harrison

Chief Executive officer

Ian Nicholson

Chairman

A message from Chairman and Chief Executive

This year has been particularly noteworthy as our historic core business has faced some challenges in downstream markets, particularly in China.

Meanwhile, our research and commercialisation of antibodies in the field of neurology has yielded significant progress. The vision of our customers for growth in this exciting field together with the performance of our antibodies at many of our customers points to future success in this area.

— Ian Nicholson & Peter Harrison